freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
=== Early research === In 1966, for the first time, Ammann and Richard E. Stiehm documented Immunoglobulin A (IgA) as the major immunoglobulin class in breastmilk, present in high concentrations in colostrum mature breastmilk. They postulated that the protection afforded to infants by breast-feeding was a result of exposure to local antibodies contained within IgA rather than absorption of maternal antibody into these infants circulation. Ammann, Stiehm and James D. Cherry identified that there are elevated levels of Immunoglobulin M (IgM) in the cord blood of newborn infants born with the congenital rubella syndrome. This was a major step forward in understanding the fetal immune response and developing diagnostic tools to differentiate between in utero infection with infectious agents such as rubella, toxoplasmosis and cytomegalovirus from infections acquired following birth. In 1973, Ammann led his research team to perform the first successful reconstitution of T-cell immunity in a patient with severe combined immunodeficiency. This was achieved through fetal thymus transplantation. This study demonstrated that the thymus holds only the potential of developing T cells and will not result in reconstitution of B cell immunity as was subsequently shown by others who utilized bone marrow transplantation, which contained multi-potential stem cells.
== History == Crisaborole was developed by Anacor Pharmaceuticals for the topical treatment of psoriasis. During preclinical and clinical development, crisaborole was called AN2728 and PF-06930164. The drug was assumed to be potential $2bn-a-year blockbuster, when Pfizer acquired Anacor Pharmaceuticals. However, the drug was commercially not successful, reaching only US$147 million in sales in 2018, and US$138 million in sales in 2019. Crisaborole was approved for use in the United States in December 2016 and for use in Canada in June 2018. The safety and efficacy of crisaborole were established in two placebo-controlled trials with a total of 1,522 participants ranging in age from two years of age to 79 years of age, with mild to moderate atopic dermatitis. In both trials participants received treatment with either crisaborole or placebo twice daily for 28 days. Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed. Overall, participants receiving crisaborole achieved greater response with clear or almost clear skin after 28 days of treatment. The trials were conducted in the US. Crisaborole, approved for the treatment of mild to moderate atopic dermatitis in the European Union, has been rapidly withdrawn from the European market (March 2020 - February 2022).
Gamma irradiation is widely used due to its high penetration depth and dose uniformity, allowing for large-scale applications with high throughput. Additionally, gamma irradiation is significantly less expensive than using an X-ray source. In most designs, the radioisotope, contained in stainless steel pencils, is stored in a water-filled storage pool which absorbs the radiation energy when not in use. For treatment, the source is lifted out of the storage tank, and product contained in totes is passed around the pencils to achieve required processing. Treatment costs vary as a function of dose and facility usage. A pallet or tote is typically exposed for several minutes to hours depending on dose. Low-dose applications such as disinfestation of fruit range between US$0.01/lb and US$0.08/lb while higher-dose applications can cost as much as US$0.20/lb.
In the past, fishing vessels were restricted in range by the simple consideration that the catch must be returned to port before it spoils and becomes worthless. The development of refrigeration and freezing technologies transformed the commercial fishing industry: fishing vessels could be larger, spending more time away from port and therefore accessing fish stocks at a much greater distance. Refrigeration and freezing also allow the catch to be distributed to markets further inland, reaching customers who previously would have had access only to dried or salted sea fish. Canning, developed during the 19th century, has also had a significant impact on fishing by allowing seasonal catches of fish that are possibly far from large centres of population to be exploited. For example: canned sardines. Preservation techniques are needed to prevent fish spoilage and lengthen shelf life. They are designed to inhibit the activity of spoilage bacteria and the metabolic changes that result in the loss of fish quality. Spoilage bacteria are the specific bacteria that produce the unpleasant odours and flavours associated with spoiled fish. Fish normally host many bacteria that are not spoilage bacteria, and most of the bacteria present on spoiled fish played no role in the spoilage. To flourish, bacteria need the right temperature, sufficient water and oxygen, and surroundings that are not too acidic. Preservation techniques work by interrupting one or more of these needs. Preservation techniques can be classified as follows.
Sources: en.wikipedia.org
The spine ends at the caudal peduncle, distinguishing this group from other fish in which the spine extends into the upper lobe of the tail fin. Teleosts have adopted a range of reproductive strategies. Most use external fertilisation: the female lays a batch of eggs, the male fertilises them and the larvae develop without any further parental involvement. A fair proportion of teleosts are sequential hermaphrodites, starting life as females and transitioning to males at some stage, with a few species reversing this process. A small percentage of teleosts are viviparous and some provide parental care with typically the male fish guarding a nest and fanning the eggs to keep them well-oxygenated. Teleosts are economically important to humans, as is shown by their depiction in art over the centuries. The fishing industry harvests them for food, and anglers attempt to capture them for sport. Some species are farmed commercially, and this method of production is likely to be increasingly important in the future. Others are kept in aquariums or used in research, especially in the fields of genetics and developmental biology.
== Contraindications == Contraindications to subcutaneous injections primarily depend on the specific medication being administered. Doses which would require more than 2 mL to be injected at once are not administered subcutaneously. Medications which may cause necrosis or otherwise be damaging or irritating to tissues should also not be administered subcutaneously. An injection should not be given at a specific site if there is inflammation or skin damage in the area.
Notable research at Einstein includes a seminal paper that helped identify nicotine as the prime addictive component of tobacco and a series of studies that uncovered the immunological basis for transplant rejection. Thymosins were discovered in Abraham White's lab at Einstein in 1966. In 1968, after observing elevated hemoglobin A1c in a diabetes patient, Samuel Rahbar confirmed this initial finding at Einstein with Helen Ranney and first structurally characterized A1c. A1c tests are now the primary method of diabetes management. In 1979, the mechanism of taxol—one of the World Health Organization's Essential Medicines—was identified by Susan Band Horwitz at Einstein. During the 1980s, Einstein researchers made significant discoveries on the emerging HIV/AIDS pandemic due to its high prevalence in the Bronx. These include the first description of pediatric HIV/AIDS and crucial work on mother-to-child transmission, links with substance abuse and men who have sex with men, and the role of opportunistic infections like tuberculosis. Mycobacterium—a bacterial genus that includes the species that cause tuberculosis and leprosy—was first genetically manipulated at Einstein by William Jacobs Jr. His large family of Mycobacterium strains (such as mc2155) are named for Einstein's mass–energy equivalence formula: E = mc2. With Paul Alan Cox, Einstein professor Oliver Sacks proposed that Lytico-bodig disease in the Chamorro people may be caused by consumption of flying foxes that had ingested cycad neurotoxins.
The primary purpose of a tablet counter (also known as a pill counter or drug counter) is to accurately count prescription medications in tablet or capsule form to aid the requirement for patient medication safety, to increase efficiency and reduce costs for the typical pharmacy. Newer versions of this counting device include advanced software to continue to improve safety for the patient who is receiving the prescription, ensuring that the pharmacy staff dispense the right medication at correct dosage strength for the right patient. (see also medication safety). Today's pharmacy industry recognizes the need for heightened vigilance against medication errors across the entire spectrum. A wealth of research has been conducted regarding the prevalence of medication errors and the ability of technology to decrease or eliminate such errors. (See the March 2003 landmark study by Auburn University's Center for Pharmacy Operations and Designs). Prescription dispensing safety and accuracy in the pharmacy are an essential part of ensuring the right patient gets the right medication at the right dosage. A trend in pharmacy is to place a greater reliance on technology and pharmacy automation to minimize the chance of human error and speed up the process of dispensing. Pharmacy management generally sees technology as a solution to industry challenges like staffing shortages, prescription volume increases, long and hectic work hours and complicated insurance reimbursement procedures.
=== Plan-generate-test paradigm === The plan-generate-test paradigm is the basic organization of the problem-solving method, and is a common paradigm used by both Heuristic Dendral and Meta-Dendral systems. The generator (later named CONGEN) generates potential solutions for a particular problem, which are then expressed as chemical graphs in Dendral. However, this is feasible only when the number of candidate solutions is minimal. When there are large numbers of possible solutions, Dendral has to find a way to put constraints that rules out large sets of candidate solutions. This is the primary aim of Dendral planner, which is a “hypothesis-formation” program that employs “task-specific knowledge to find constraints for the generator”. Last but not least, the tester analyzes each proposed candidate solution and discards those that fail to fulfill certain criteria. This mechanism of plan-generate-test paradigm is what holds Dendral together.
Sources: en.wikipedia.org
== Chemical properties == Pentoxyverine dihydrogen citrate, the salt that is commonly used for oral preparations, is a white to off-white, crystalline powder. It dissolves easily in water or chloroform, but not in benzene, diethyl ether, or petroleum ether. It melts at 90 to 95 °C (194 to 203 °F). Other orally available salts are the hydrochloride and the tannate; suppositories contain the free base.
In β− decay, the weak interaction converts an atomic nucleus into a nucleus with atomic number increased by one, while emitting an electron (e−) and an electron antineutrino (νe). β− decay generally occurs in neutron-rich nuclei. The generic equation is:
=== Final weeks on the Gulf Coast === Filming resumed on July 19. The sandpit fight scene between Bosworth and pro wrestler Tom Magee was shot in Bay St. Louis. It was aborted after a first attempt where Bosworth clipped Magee's cheek with a punch, and finished two weeks later on August 9. While a King Features gossip column claimed that the botch had led to a real scuffle, Bosworth himself assured that the accident had been handled in a civil manner by both. The final scene shot on the Gulf Coast was a gas station explosion on Daisy Vestry Road in Latimer on August 10.
== Major branches == Modern neuroscience education and research activities can be very roughly categorized into the following major branches, based on the subject and scale of the system in examination as well as distinct experimental or curricular approaches. Individual neuroscientists, however, often work on questions that span several distinct subfields.
Most of the isotopes of each chemical element present in the Earth today were formed by such processes no later than the time of our planet's condensation from the solar protoplanetary disc, around 4.5 billion years ago. The exceptions to these so-called primordial elements are those that have resulted from the radioactive disintegration of unstable parent nuclei as they progress down one of several decay chains, each of which terminates with the production of one of the 251 stable isotopes known to exist. Aside from cosmic or stellar nucleosynthesis, and decay chains the only other ways of producing a chemical element rely on atomic weapons, nuclear reactors (natural or manmade) or the laborious atom-by-atom assembly of nuclei with particle accelerators. Unstable isotopes decay to their daughter products (which may sometimes be even more unstable) at a given rate; eventually, often after a series of decays, a stable isotope is reached: there are 251 stable isotopes in the universe. In stable isotopes, light elements typically have a lower ratio of neutrons to protons in their nucleus than heavier elements. Light elements such as helium-4 have close to a 1:1 neutron:proton ratio. The heaviest elements such as uranium have close to 1.5 neutrons per proton (e.g. 1.587 in uranium-238). No nuclide heavier than lead-208 is stable; these heavier elements have to shed mass to achieve stability, mostly by alpha decay.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.